NovaBay Pharmaceuticals, Inc. – FDA Warning Letter, Oct 27, 2020
The FDA and FTC issued a Warning Letter to NovaBay Pharmaceuticals, Inc. on November 2, 2020, following reviews of their websites (novabay.com, avenova.com, saniteyesmore.com) and social media (Facebook, Twitter) between September 22-24, 2020, and October 27, 2020. The letter also noted product availability on Amazon and Walmart.
The letter identifies AVENOVA® ANTIMICROBIAL LID & LASH SOLUTION, PURE HYPOCHLOROUS ACID, 0.01%, 20 ml, as an unapproved new drug and a misbranded drug. The product is marketed with claims to mitigate, prevent, treat, diagnose, or cure COVID-19, which violates sections 505(a) and 502 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a) and § 352. The introduction of this product into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).
The FDA and FTC demand immediate cessation of sales for these unapproved and unauthorized COVID-19 related products. NovaBay
ID · 3ed50718-3418-4b99-927b-b06b8907bed0
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.